These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38608171)

  • 21. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
    Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
    J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
    Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
    J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women.
    Kwatra G; Adrian PV; Shiri T; Buchmann EJ; Cutland CL; Madhi SA
    Clin Microbiol Infect; 2015 Jun; 21(6):568.e13-21. PubMed ID: 25680313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS colonisation of vaginal epithelial cells.
    Deifallah Yousif M; Felek A; Saydam M; Wilson S; Murdan S; Mawas F
    Vaccine; 2022 Oct; 40(42):6055-6063. PubMed ID: 36096970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
    Absalon J; Segall N; Block SL; Center KJ; Scully IL; Giardina PC; Peterson J; Watson WJ; Gruber WC; Jansen KU; Peng Y; Munson S; Pavliakova D; Scott DA; Anderson AS
    Lancet Infect Dis; 2021 Feb; 21(2):263-274. PubMed ID: 32891191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable.
    Haeusler IL; Daniel O; Isitt C; Watts R; Cantrell L; Feng S; Cochet M; Salloum M; Ikram S; Hayter E; Lim S; Hall T; Athaide S; Cosgrove CA; Tregoning JS; Le Doare K
    Clin Exp Immunol; 2022 Aug; 209(2):188-200. PubMed ID: 35802786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infant serotype specific anti-capsular immunoglobulin G antibody and risk of invasive group B Streptococcal disease.
    Dangor Z; Kwatra G; Izu A; Khan M; Lala SG; Madhi SA
    Vaccine; 2021 Nov; 39(47):6813-6816. PubMed ID: 34688499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus.
    Amaya RA; Baker CJ; Keitel WA; Edwards MS
    J Am Geriatr Soc; 2004 Jan; 52(1):46-50. PubMed ID: 14687314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
    Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
    J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons.
    Edwards MS; Rench MA; Palazzi DL; Baker CJ
    Clin Infect Dis; 2005 Feb; 40(3):352-7. PubMed ID: 15668856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
    Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
    Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
    Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
    Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
    Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
    Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.
    Paoletti LC; Pinel J; Johnson KD; Reinap B; Ross RA; Kasper DL
    J Infect Dis; 1999 Sep; 180(3):892-5. PubMed ID: 10438388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Infect Immun; 2001 Jan; 69(1):297-306. PubMed ID: 11119518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.
    Guttormsen HK; Baker CJ; Nahm MH; Paoletti LC; Zughaier SM; Edwards MS; Kasper DL
    Infect Immun; 2002 Apr; 70(4):1724-38. PubMed ID: 11895934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine.
    Jang AY; Choi MJ; Zhi Y; Ji HJ; Noh JY; Yoon JG; Cheong HJ; Kim WJ; Seo HS; Song JY
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34064299
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.
    Baker CJ; Rench MA; McInnes P
    Vaccine; 2003 Jul; 21(24):3468-72. PubMed ID: 12850362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.